|
|
Autism Research Institute
Autism Research Review International
1987 to 2004, Volumes 1 to 18
S
saccades, 1988, Vol. 02(4) pp. 4; 2004, Vol. 18(3) pp. 4.
SAD (seasonal affective disorder), 1999, Vol. 13(1) pp. 4
SAFE Minds, 2000, Vol. 14(4) pp. 7; 2001, Vol. 15(3) pp. 1; 2001, Vol. 15(4) pp. 1.
Sahelian, Ray, 1999, Vol. 13(1) pp. 2
Sahley, Tony, 1987, Vol. 01(2) pp. 6
Sanberg, P. R., 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(4) pp. 2.
Sanchez, Laura E., 1996, Vol. 10(3) pp. 1; 1996, Vol. 10(4) pp. 4.
Sanchez-Forte, M., 1997, Vol. 11(4) pp. 7
Sanders, Matthew R., 1989, Vol. 03(3) pp. 5
Sandler, Adrian, 1999, Vol. 13(4) pp. 7; 2000, Vol. 14(2) pp. 3.
Sandler, Richard H., 2000, Vol. 14(3) pp. 2
Sandman, Curt, 1987, Vol. 01(2) pp. 6; 1992, Vol. 06(1) pp. 1.
Sandyk, R., 1997, Vol. 11(4) pp. 7
Santangelo, Susan, 1995, Vol. 09(4) pp. 4
Santarcangelo, Suzanne, 1989, Vol. 03(2) pp. 5
Santorum, Rick (U.S. Senator), 2004, Vol. 18(4) pp. 3
Sanua, Victor, 1989, Vol. 03(3) pp. 3; 1990, Vol. 04(1) pp. 7.
SARS (severe acute respiratory syndrome), 2003, Vol. 17(1) pp. 7
Sasso, Gary M., 1992, Vol. 06(4) pp. 1
Satoh, Minoru, 2003, Vol. 17(3) pp. 5
Sauvage, D., 1990, Vol. 04(1) pp. 7
savants
abilities and normal skill acquisition, 1999, Vol. 13(2) pp. 2
attention in, 1989, Vol. 03(1) pp. 2
autistic-crypto savants, 1990, Vol. 04(1) pp. 3
brain abnormalities in, 1989, Vol. 03(1) pp. 2
decision-making difficulties for, 1998, Vol. 12(3) pp. 6
general discussion, 1999, Vol. 13(2) pp. 3
and multi-handicapped people, 1989, Vol. 03(1) pp. 1
normal abilities in, 1989, Vol. 03(1) pp. 1
prevalence among kinds of autistics, 1989, Vol. 03(1) pp. 1
"prodigious" and "talented" compared, 1989, Vol. 03(1) pp. 1
techniques used by, 1987, Vol. 01(1) pp. 2; 1989, Vol. 03(1) pp. 2.
Schaefer, Virginie, 1994, Vol. 08(1) pp. 6
Schafer, Lenny, 2003, Vol. 17(3) pp. 3
Schafer Autism Report, 2003, Vol. 17(3) pp. 3
Schaumann, Helen, 1988, Vol. 02(1) pp. 2
Schaumburg, H., 1996, Vol. 10(3) pp. 3
Schawlow, Arthur, 1988, Vol. 02(1) pp. 3; 1994, Vol. 08(4) pp. 3.
schedule, every-other-day, 1996, Vol. 10(2) pp. 5
Schellenberg, Rudiger
Schilder, A, 1994, Vol. 08(4) pp. 1
schizocehaly, 1990, Vol. 04(3) pp. 4
schizophrenia
and autism, 1987, Vol. 01(3) pp. 4; 1989, Vol. 03(4) pp. 4; 1995, Vol. 09(2) pp. 4.
and Borna virus, 1996, Vol. 10(3) pp. 5; 1997, Vol. 11(2) pp. 2.
and celiac disease, 2004, Vol. 18(1) pp. 4
and choking death, 2003, Vol. 17(4) pp. 5
Delta (9)-THC (tetrahydrocannabinol) for, 2003, Vol. 17(1) pp. 4
and essential fatty acid levels, 1999, Vol. 13(1) pp. 7
and lead poisoning, 2004, Vol. 18(1) pp. 4
mecamylamine for, 1998, Vol. 12(4) pp. 2
and milk and wheat proteins, 1999, Vol. 13(2) pp. 1
negative symptoms vs. social deficits in autism, 1997, Vol. 11(3) pp. 4
omega-3-fatty acids for, 1999, Vol. 13(1) pp. 7
Pepcid for, 1997, Vol. 11(3) pp. 4
reelin gene variant, 2001, Vol. 15(2) pp. 1–2
supplements for, 1996, Vol. 10(2) pp. 5; 1998, Vol. 12(2) pp. 3.
symptoms precipitated by marijuana, 2003, Vol. 17(1) pp. 3
Schlanger, S., 2002, Vol. 16(3) pp. 4
Schleien, Stuart J., 1990, Vol. 04(1) pp. 5
Schmid, Franz, 1997, Vol. 11(3) pp. 3
Schmitt, J. E., 2001, Vol. 15(4) pp. 4
Schneider, C. K., 2000, Vol. 14(3) pp. 6
Schnitzler, Eugene R., 1987, Vol. 01(3) pp. 2
schools. See also education
Schools Are for Everyone (organization), 1993, Vol. 07(4) pp. 2
Schopler, Eric
on aversives, 1988, Vol. 02(3) pp. 3
award, 1995, Vol. 09(2) pp. 3
on facilitated communication, 1992, Vol. 06(3) pp. 1
on full inclusion, 1994, Vol. 08(4) pp. 2
on Lovaas' study, 1987, Vol. 01(3) pp. 6; 1998, Vol. 12(2) pp. 6; 1998, Vol. 12(3) pp. 7.
Schreibman, Laura
on aversives, 1988, Vol. 02(3) pp. 2
picture books, 1994, Vol. 08(3) pp. 7
pivotal response training research, 1992, Vol. 06(2) pp. 5
self-monitoring for behaviors, 1990, Vol. 04(2) pp. 5
stimulus overselectivity finding, 1988, Vol. 02(1) pp. 5; 1994, Vol. 08(4) pp. 5.
Schreier, Herbert A., 1999, Vol. 13(1) pp. 5
Schroer, Richard J., 1998, Vol. 12(3) pp. 4
Schulman, Randy L., 1996, Vol. 10(4) pp. 4
Schultz, Nicole, 1992, Vol. 06(1) pp. 7
Schultz, Pierre, 1991, Vol. 05(1) pp. 4
Schultz, Robert T., 2000, Vol. 14(2) pp. 6
Schultz, Susan K., 2001, Vol. 15(1) pp. 5
Schultz-Pedersen, Soren, 2001, Vol. 15(4) pp. 6
Schumann, C.M., 2004, Vol. 18(2) pp. 2
Schutzehofer, Karen Kelly, 1990, Vol. 04(1) pp. 7
Schwam, Jeffrey S., 1996, Vol. 10(1) pp. 7
Schwartz, Jeffrey, 1996, Vol. 10(1) pp. 5
Schwartz, Miguel, 1995, Vol. 09(2) pp. 4
Schwarzenegger, Arnold (CA. governor), 2004, Vol. 18(3) pp. 1
Schweitzer, Robert, 1991, Vol. 05(3) pp. 6
science metaphors, 2000, Vol. 14(4) pp. 3
Scifo, R., 1992, Vol. 06(2) pp. 2
Scotopic Sensitivity Syndrome, 1995, Vol. 09(4) pp. 6
Scott, Derek W., 1989, Vol. 03(2) pp. 4
Scott, Fiona J., 1997, Vol. 11(1) pp. 7
Scragg, Peter, 1995, Vol. 09(2) pp. 6
screaming, 2000, Vol. 14(1) pp. 5
seafood, 2001, Vol. 15(4) pp. 7
seasonal affective disorder (SAD), 1999, Vol. 13(1) pp. 4
seborrheic dermatitis, 1998, Vol. 12(1) pp. 4
Secan, Kristin E., 1987, Vol. 01(2) pp. 5
Secret Fallout (Sternglass), 1989, Vol. 03(4) pp. 5
Secret Night World of Cats (Landalf, illustrated by Rimland), 1998, Vol. 12(2) pp. 7; 1998, Vol. 12(3) pp. 5; 1999, Vol. 13(1) pp. 4.
secretin
for anti-gliadin IgG positive children, 2000, Vol. 14(3) pp. 6
for attention, 1998, Vol. 12(3) pp. 3
for behaviors, 2000, Vol. 14(1) pp. 7
biomarker for, 2001, Vol. 15(2) pp. 1; 2004, Vol. 18(1) pp. 3.
and brain, 2004, Vol. 18(2) pp. 2
and brain function, 2001, Vol. 15(4) pp. 1–2, 6
clinical trials, 2000, Vol. 14(1) pp. 7; 2002, Vol. 16(2) pp. 2; 2002, Vol. 16(4) pp. 4; 2004, Vol. 18(1) pp. 3.
for communication disorders, 1998, Vol. 12(2) pp. 1; 2000, Vol. 14(1) pp. 7.
for digestive problems, 1999, Vol. 13(4) pp. 3; 2000, Vol. 14(1) pp. 7; 2002, Vol. 16(3) pp. 2.
for eye contact, 2000, Vol. 14(1) pp. 7
and FDA, 2001, Vol. 15(3) pp. 4
general discussion, 1998, Vol. 12(3) pp. 3; 1998, Vol. 12(4) pp. 3; 1999, Vol. 13(1) pp. 3; 1999, Vol. 13(4) pp. 7.
HCL-pepsin for production of, 1998, Vol. 12(4) pp. 7
for language disorders, 1999, Vol. 13(1) pp. 3; 2000, Vol. 14(2) pp. 3; 2000, Vol. 14(3) pp. 6.
negative placebo effect, 2000, Vol. 14(2) pp. 3
Parker Beck story, 1998, Vol. 12(3) pp. 3
patent for, 1999, Vol. 13(1) pp. 3
safety of, 1999, Vol. 13(4) pp. 3; 2000, Vol. 14(3) pp. 6.
and seizure drugs compared, 1998, Vol. 12(4) pp. 3
for speech, 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(3) pp. 3; 1998, Vol. 12(4) pp. 3; 1999, Vol. 13(1) pp. 3; 1999, Vol. 13(4) pp. 7.
supply of, 1999, Vol. 13(1) pp. 3; 1999, Vol. 13(3) pp. 2.
synthetic form's advantages, 1999, Vol. 13(4) pp. 3
for tantrums, 1999, Vol. 13(1) pp. 3
treatment candidates, 1998, Vol. 12(2) pp. 1; 2002, Vol. 16(3) pp. 2.
and urinary 7-methylxanthine, 2000, Vol. 14(3) pp. 6
Secretin Outcomes Survey (SOS), 1998, Vol. 12(4) pp. 3; 1999, Vol. 13(3) pp. 2.
secretory otitis media, 1992, Vol. 06(4) pp. 4
secure employment, 1990, Vol. 04(3) pp. 2
segregation. See inclusion
Sehnert, Keith W., 1989, Vol. 03(1) pp. 6
Seip, Jo-Anne Lydia, 1998, Vol. 12(3) pp. 6
seizure disorders. See also epilepsy
anti-convulsants for, 1992, Vol. 06(4) pp. 7; 1994, Vol. 08(3) pp. 2.
and antiphospholipid antibodies, 2001, Vol. 15(1) pp. 7
and aplastic anemia, 1994, Vol. 08(3) pp. 2
calcium for, 1990, Vol. 04(1) pp. 2
dietary interventions, 1991, Vol. 05(4) pp. 2; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(1) pp. 5.
DMG for, 1990, Vol. 04(2) pp. 3; 1993, Vol. 07(1) pp. 7; 1995, Vol. 09(4) pp. 3.
early evaluation crucial, 1988, Vol. 02(1) pp. 2; 1997, Vol. 11(3) pp. 4.
from Epstein-Barr infections, 2001, Vol. 15(1) pp. 4
estrogen and, 2003, Vol. 17(1) pp. 4
felbamate for, 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(2) pp. 7; 1994, Vol. 08(3) pp. 2.
fenfluramine and, 1987, Vol. 01(3) pp. 2
and HUFA (highly unsaturated fatty acids), deficiency of, 2000, Vol. 14(4) pp. 6
and IQ, 1990, Vol. 04(1) pp. 4
lamotrigine for, 1998, Vol. 12(2) pp. 5
Landau-Kleffner syndrome, 1996, Vol. 10(S) pp.
Lennox-Gastaut syndrome, 1994, Vol. 08(2) pp. 7
levetiracetam (Keppra) for, 2002, Vol. 16(4) pp. 4
melatonin for, 1994, Vol. 08(3) pp. 1
mood improvement for, 2001, Vol. 15(2) pp. 7
peptides and, 1991, Vol. 05(4) pp. 2
and phenobarbital, 1990, Vol. 04(1) pp. 6; 1993, Vol. 07(4) pp. 5.
phenytoin (Dilantin) for, 2001, Vol. 15(4) pp. 4
regression and, 1997, Vol. 11(3) pp. 4
Rett Syndrome, 1987, Vol. 01(2) pp. 6; 1998, Vol. 12(2) pp. 5.
and secretin, 1999, Vol. 13(1) pp. 3
surgery for, 1996, Vol. 10(2) pp. 7; 1996, Vol. 10(3) pp. 5; 1997, Vol. 11(3) pp. 4.
and tetanus neurotoxins, 1998, Vol. 12(4) pp. 1
and Tourette's, 1991, Vol. 05(3) pp. 2; 1992, Vol. 06(1) pp. 4; 1995, Vol. 09(4) pp. 3.
tuberous sclerosis, 1993, Vol. 07(3) pp. 4; 2001, Vol. 15(4) pp. 4.
types of, 1990, Vol. 04(1) pp. 4; 1992, Vol. 06(4) pp. 7; 1994, Vol. 08(1) pp. 1; 1994, Vol. 08(3) pp. 1.
ventricular enlargement and, 1987, Vol. 01(4) pp. 6
vitamin B6 for, 1994, Vol. 08(1) pp. 1; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(3) pp. 3.
seizures
anticonvulsants for, 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(2) pp. 7; 1996, Vol. 10(2) pp. 6; 2002, Vol. 16(2) pp. 5; 2002, Vol. 16(4) pp. 4.
and antidepressants, 1992, Vol. 06(3) pp. 4; 1993, Vol. 07(4) pp. 1.
and antipsychotics, 1996, Vol. 10(1) pp. 1; 1996, Vol. 10(3) pp. 2; 1999, Vol. 13(4) pp. 4.
and aspartame, 1992, Vol. 06(2) pp. 4
Atkins diet and, 2004, Vol. 18(1) pp. 2
autistic behaviors as, 1992, Vol. 06(1) pp. 4; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(2) pp. 6.
as autoimmune phenomena, 2001, Vol. 15(1) pp. 7
cannabinoids for, 2003, Vol. 17(4) pp. 4
chromosome 15 defect in autistics with, 1998, Vol. 12(3) pp. 4
diets for, 1996, Vol. 10(1) pp. 5; 2002, Vol. 16(2) pp. 5.
DMG for, 1990, Vol. 04(2) pp. 3; 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(3) pp. 2; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(2) pp. 1.
and echolalia, 1992, Vol. 06(1) pp. 4
focal seizures, 2002, Vol. 16(2) pp. 5
and food intolerances, 1995, Vol. 09(4) pp. 3
forced normalization syndrome, 1999, Vol. 13(3) pp. 4
and galanin, 2003, Vol. 17(3) pp. 4
gene therapy for, 2003, Vol. 17(3) pp. 4
from iron overload in utero, 2001, Vol. 15(3) pp. 6
ketogenic diet for, 1996, Vol. 10(1) pp. 5; 2002, Vol. 16(2) pp. 5.
L-carnosine for, 2003, Vol. 17(1) pp. 1
in Landau-Kleffner Syndrome, 1996, Vol. 10(2) pp. 6
magnesium for, 1995, Vol. 09(4) pp. 3
marijuana for, 2003, Vol. 17(4) pp. 4
and melatonin, 1997, Vol. 11(4) pp. 7; 1999, Vol. 13(4) pp. 6.
myoclonic seizures, 1996, Vol. 10(1) pp. 5
and opiates, 1992, Vol. 06(1) pp. 1
prediction of, 2001, Vol. 15(2) pp. 7
and psychiatric risks, 1999, Vol. 13(3) pp. 4
PUFA (omega-3 polyunsaturated fatty acid) nutritional spread for, 2002, Vol. 16(3) pp. 4
and secretin, 1999, Vol. 13(4) pp. 3
and self-injuring behaviors, 1993, Vol. 07(1) pp. 4
and sleep disorders, 1998, Vol. 12(4) pp. 4
sound sensitivity from, 2001, Vol. 15(3) pp. 4
and stress, 1993, Vol. 07(1) pp. 4
and tricyclics, 1992, Vol. 06(3) pp. 4
and vaccines, 1995, Vol. 09(1) pp. 7; 2003, Vol. 17(2) pp. 2.
vagus nerve stimulator for, 1997, Vol. 11(4) pp. 2; 2001, Vol. 15(2) pp. 7; 2002, Vol. 16(3) pp. 5.
vitamin B6 for, 1994, Vol. 08(1) pp. 1; 1995, Vol. 09(3) pp. 6; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(2) pp. 1; 1996, Vol. 10(3) pp. 3.
vitamin D for, 2004, Vol. 18(3) pp. 4
selective serotonin reputake inhibitors (SSRIs)
and behavior problems, 1997, Vol. 11(2) pp. 4
for communication, 1996, Vol. 10(4) pp. 2
and dental disease, 1998, Vol. 12(1) pp. 7
and diuretics, 2004, Vol. 18(1) pp. 5
fluxetine (Prozac), 1996, Vol. 10(4) pp. 7
and gastrointestinal bleeding, 1999, Vol. 13(4) pp. 4
for language, 1996, Vol. 10(4) pp. 2
and movement disorders, 1997, Vol. 11(1) pp. 4
and other drugs compared, 1996, Vol. 10(4) pp. 2
for self-help skills, 1996, Vol. 10(4) pp. 2
sertraline (Zoloft), 1996, Vol. 10(4) pp. 2
and sleep difficulties, 1997, Vol. 11(2) pp. 4
for social deficits, 1996, Vol. 10(4) pp. 2
and suicidal impulses in children, 2004, Vol. 18(1) pp. 2
and surgery, 2004, Vol. 18(1) pp. 4
and tardive dyskinesia, 1996, Vol. 10(4) pp. 7
withdrawal symptoms, 1998, Vol. 12(2) pp. 6
selenium, 2002, Vol. 16(3) pp. 7
self-assessment, 1988, Vol. 02(4) pp. 5
self-care
bill paying, 1987, Vol. 01(1) pp. 5
cooking, 1989, Vol. 03(3) pp. 5
grocery shopping, 1993, Vol. 07(4) pp. 4
on job, 1990, Vol. 04(3) pp. 6
menstrual training, 1990, Vol. 04(2) pp. 5; 1998, Vol. 12(1) pp. 7.
picture books for, 1994, Vol. 08(3) pp. 7
pill taking tips, 2001, Vol. 15(4) pp. 7
safety training needed for developmentally disabled people, 2000, Vol. 14(2) pp. 7
sensory integration and, 1991, Vol. 05(2) pp. 6
sleep problems and, 1993, Vol. 07(3) pp. 5
vitamin B6 and, 1993, Vol. 07(1) pp. 7
self-determination, 1991, Vol. 05(2) pp. 5
self-injury
ACTH and, 1998, Vol. 12(1) pp. 6
addiction theory of, 1992, Vol. 06(1) pp. 1; 1998, Vol. 12(1) pp. 6.
and allergies, 1997, Vol. 11(4) pp. 5
anesthetic cream for, 2003, Vol. 17(4) pp. 5
aversives for, 1988, Vol. 02(3) pp. 1; 1989, Vol. 03(4) pp. 1; 1990, Vol. 04(1) pp. 7; 1992, Vol. 06(2) pp. 5.
brain damage from, 1992, Vol. 06(2) pp. 4
calcium for, 1990, Vol. 04(1) pp. 2; 1995, Vol. 09(1) pp. 4; 1998, Vol. 12(3) pp. 6.
calm sitting for, 1988, Vol. 02(3) pp. 5
choice expansion for, 1994, Vol. 08(3) pp. 5
communication skills and, 1989, Vol. 03(4) pp. 6
from constipation, 2003, Vol. 17(1) pp. 7
as cyclical, 1995, Vol. 09(1) pp. 4
diets for, 1999, Vol. 13(2) pp. 6; 2002, Vol. 16(2) pp. 7.
DMG for, 1992, Vol. 06(1) pp. 6; 1992, Vol. 06(2) pp. 6.
drugs (anti-anxiety) for, 1991, Vol. 05(4) pp. 4
drugs (anti-convulsant) for, 1990, Vol. 04(2) pp. 2; 1993, Vol. 07(1) pp. 4.
drugs (anti-depressant) for, 1992, Vol. 06(1) pp. 5; 1992, Vol. 06(3) pp. 4; 1993, Vol. 07(3) pp. 2; 1996, Vol. 10(4) pp. 4; 1998, Vol. 12(1) pp. 4; 2002, Vol. 16(2) pp. 7.
sertraline (Zoloft) for, 1996, Vol. 10(4) pp. 2
drugs (clonidine) for, 2000, Vol. 14(1) pp. 4
drugs (clozapine) for, 1996, Vol. 10(1) pp. 1; 1996, Vol. 10(3) pp. 2.
drugs (haloperidol) for, 1990, Vol. 04(1) pp. 1
drugs (lithium) for, 1989, Vol. 03(3) pp. 4
drugs (naloxone) for, 1987, Vol. 01(2) pp. 6; 1988, Vol. 02(2) pp. 4; 1992, Vol. 06(1) pp. 1.
drugs (naltrexone) for: equivocal findings, 1988, Vol. 02(2) pp. 4; 1990, Vol. 04(4) pp. 4; 1994, Vol. 08(1) pp. 4; 1995, Vol. 09(2) pp. 2.
drugs (naltrexone) for: negative findings, 1996, Vol. 10(1) pp. 4
drugs (naltrexone) for: positive findings, 1988, Vol. 02(2) pp. 4; 1989, Vol. 03(3) pp. 2; 1990, Vol. 04(1) pp. 1; 1990, Vol. 04(2) pp. 1; 1990, Vol. 04(4) pp. 4; 1991, Vol. 05(1) pp. 4; 1991, Vol. 05(3) pp. 4; 1991, Vol. 05(4) pp. 2; 1992, Vol. 06(1) pp. 1; 1992, Vol. 06(2) pp. 2; 1996, Vol. 10(1) pp. 4; 1998, Vol. 12(1) pp. 6; 2001, Vol. 15(1) pp. 5; 2001, Vol. 15(3) pp. 7.
drugs (OCD) for, 1991, Vol. 05(1) pp. 4
drugs (olanzapine) for, 1999, Vol. 13(3) pp. 4; 2001, Vol. 15(1) pp. 4.
drugs (risperidone) for, 1996, Vol. 10(2) pp. 2; 1997, Vol. 11(2) pp. 6; 2000, Vol. 14(1) pp. 5.
and frontal lobe seizures, 1992, Vol. 06(1) pp. 4; 1995, Vol. 09(4) pp. 3.
head banging, 1987, Vol. 01(3) pp. 1; 1988, Vol. 02(3) pp. 3; 1989, Vol. 03(1) pp. 5; 1989, Vol. 03(4) pp. 6.
HSP 3012, 1996, Vol. 10(4) pp. 1–2
jobs as incentive against, 1990, Vol. 04(3) pp. 1
magnesium for, 1992, Vol. 06(1) pp. 7; 1992, Vol. 06(2) pp. 6; 1994, Vol. 08(4) pp. 7.
as manipulative ploy, 1993, Vol. 07(2) pp. 5
marijuana for, 2002, Vol. 16(2) pp. 7; 2003, Vol. 17(1) pp. 3.
mood music for, 1998, Vol. 12(1) pp. 5
"more effort" restraint for, 2000, Vol. 14(2) pp. 5
mouthguards for, 1991, Vol. 05(3) pp. 5
and neuropathy, 2001, Vol. 15(3) pp. 7
NIH report on, 1992, Vol. 06(2) pp. 1
nonaversives for, 1987, Vol. 01(4) pp. 5
opioids and, 1987, Vol. 01(2) pp. 1; 1988, Vol. 02(2) pp. 4; 1991, Vol. 05(3) pp. 4; 1992, Vol. 06(1) pp. 1; 1993, Vol. 07(1) pp. 4; 1994, Vol. 08(1) pp. 4; 1996, Vol. 10(1) pp. 4; 1998, Vol. 12(1) pp. 6.
overcorrection for, 1988, Vol. 02(3) pp. 15
and pain, 1994, Vol. 08(3) pp. 2; 1997, Vol. 11(4) pp. 5; 1998, Vol. 12(1) pp. 6; 2001, Vol. 15(4) pp. 3.
peptide ACTH and, 1998, Vol. 12(1) pp. 6
during PMS, 1998, Vol. 12(3) pp. 6; 2000, Vol. 14(3) pp. 5; 2001, Vol. 15(1) pp. 4.
protective gear for, 1988, Vol. 02(1) pp. 5; 1994, Vol. 08(4) pp. 5.
reinforcing incompatible behaviors for, 1989, Vol. 03(1) pp. 5
room management for, 1988, Vol. 02(3) pp. 5
secretin for, 2000, Vol. 14(1) pp. 7
self-assessment for, 1988, Vol. 02(4) pp. 5
sensory integration for preventing, 1991, Vol. 05(1) pp. 5; 1997, Vol. 11(4) pp. 5.
sensory stimulation for, 1988, Vol. 02(4) pp. 6; 1995, Vol. 09(2) pp. 5.
SIBIS (deterrent device), 1987, Vol. 01(3) pp. 1; 1988, Vol. 02(3) pp. 3; 1989, Vol. 03(4) pp. 1; 1994, Vol. 08(2) pp. 4; 1995, Vol. 09(4) pp. 2; 1996, Vol. 10(2) pp. 3; 1996, Vol. 10(4) pp. 1; 1997, Vol. 11(4) pp. 1.
and sleep deprivation, 1997, Vol. 11(4) pp. 5
with vagal nerve stimulators, 2002, Vol. 16(3) pp. 5
vitamin B6 for, 1992, Vol. 06(1) pp. 6; 1992, Vol. 06(2) pp. 6; 1994, Vol. 08(4) pp. 7; 2001, Vol. 15(4) pp. 3.
self-management, 1992, Vol. 06(4) pp. 5; 2000, Vol. 14(3) pp. 5.
self-monitoring, 1990, Vol. 04(2) pp. 5; 1994, Vol. 08(1) pp. 2; 1997, Vol. 11(2) pp. 5; 1997, Vol. 11(4) pp. 5.
self-restraining behaviors, 1996, Vol. 10(4) pp. 4
self-stimulating behaviors. See also stereotypies
in Asperger's and autism compared, 1988, Vol. 02(4) pp. 7
DAN! Protocol, 1997, Vol. 11(1) pp. 6; 2000, Vol. 14(4) pp. 7.
deep pressure for, 1992, Vol. 06(4) pp. 5
DRO (differential reinforcement of other behaviors) for, 1989, Vol. 03(1) pp. 5
exercise for, 1989, Vol. 03(1) pp. 1; 1997, Vol. 11(2) pp. 5.
focusing training for, 1998, Vol. 12(1) pp. 2
massage for, 2002, Vol. 16(1) pp. 5
naltrexone for, 1991, Vol. 05(4) pp. 2
negative practice for, 1987, Vol. 01(2) pp. 5
Prozac for, 1993, Vol. 07(3) pp. 2
as rewards, 1987, Vol. 01(2) pp. 5
rings for, 1990, Vol. 04(4) pp. 5
room management for, 1988, Vol. 02(3) pp. 5
and secretin, 1999, Vol. 13(4) pp. 3
sensory integration therapy for, 1990, Vol. 04(4) pp. 5
substitutes for, 1987, Vol. 01(3) pp. 5
vitamin B6 for, 1992, Vol. 06(1) pp. 7; 1996, Vol. 10(3) pp. 7.
Selfe, Lorna, 1989, Vol. 03(1) pp. 2
Senators' contact information, 2003, Vol. 17(3) pp. 1; 2003, Vol. 17(3) pp. 1; 2004, Vol. 18(4) pp. 3.
Sensory Integration and the Child (Ayres), 1991, Vol. 05(2) pp. 3
Sensory Integration International, 1995, Vol. 09(3) pp. 6
sensory integration therapy
for attention, 1999, Vol. 13(2) pp. 5
behaviors for, 1988, Vol. 02(2) pp. 6; 1991, Vol. 05(1) pp. 5; 1991, Vol. 05(2) pp. 3; 1995, Vol. 09(2) pp. 5; 1997, Vol. 11(4) pp. 5; 1999, Vol. 13(2) pp. 5.
Center for Neurodevelopmental Studies, 1991, Vol. 05(2) pp. 6
criteria for program, 1995, Vol. 09(3) pp. 6
Sensory Motor Integration, 1988, Vol. 02(2) pp. 2
and sensory stimulation compared, 1991, Vol. 05(2) pp. 3
Snoezelen rooms and outdoor activities compared, 2001, Vol. 15(3) pp. 5
for social skills, 1999, Vol. 13(2) pp. 5
for speech, 1990, Vol. 04(4) pp. 5; 1991, Vol. 05(2) pp. 6; 1999, Vol. 13(2) pp. 5.
Temple Grandin on, 1990, Vol. 04(4) pp. 5; 1991, Vol. 05(2) pp. 3; 1995, Vol. 09(3) pp. 7.
videotape on, 1995, Vol. 09(1) pp. 6
sensory rewards, 1987, Vol. 01(1) pp. 5
sensory scrambling
sensory stimulation
separation anxiety, 1998, Vol. 12(2) pp. 2
septal nuclei, 1990, Vol. 04(1) pp. 4
SerenAid, 2000, Vol. 14(1) pp. 6
Seromycin (d-cycloserine), 2004, Vol. 18(4) pp. 5
Seroquel (quetiapine fumarate), 1999, Vol. 13(4) pp. 4; 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2.
serotonin
and acrocyanosis, 1990, Vol. 04(3) pp. 4
and aggression, 1996, Vol. 10(1) pp. 6
antibodies in autism, 1988, Vol. 02(2) pp. 4
and anxiety, 1997, Vol. 11(2) pp. 2; 1997, Vol. 11(4) pp. 2; 2000, Vol. 14(1) pp. 1.
and auditory integration training, 1995, Vol. 09(4) pp. 2
and B44-DR4 haplotype, 1996, Vol. 10(4) pp. 2
and bi-polar disorder, 1997, Vol. 11(2) pp. 2; 1997, Vol. 11(4) pp. 2; 2000, Vol. 14(1) pp. 1.
and brain abnormalities, 1987, Vol. 01(4) pp. 7; 1989, Vol. 03(4) pp. 4; 1991, Vol. 05(2) pp. 5; 1997, Vol. 11(4) pp. 4; 1999, Vol. 13(2) pp. 2.
and C4B null allele, 1996, Vol. 10(4) pp. 2
in children, 1995, Vol. 09(4) pp. 1
and depression, 1994, Vol. 08(3) pp. 4; 2004, Vol. 18(4) pp. 4.
and developmental language disorder, 1987, Vol. 01(4) pp. 6
diet rich in, 2002, Vol. 16(2) pp. 7
and dopamine, 1987, Vol. 01(4) pp. 4; 1988, Vol. 02(1) pp. 4; 1994, Vol. 08(4) pp. 4; 2003, Vol. 17(3) pp. 7.
drugs (anti-anxiety) and, 1992, Vol. 06(2) pp. 2
drugs (clomipramine), 1992, Vol. 06(2) pp. 7; 1992, Vol. 06(4) pp. 5; 1993, Vol. 07(3) pp. 1; 1993, Vol. 07(4) pp. 1.
drugs (desipramine) and, 1992, Vol. 06(2) pp. 7
drugs (eltoprazine) and, 1992, Vol. 06(2) pp. 2
drugs (fenfluramine) and, 1987, Vol. 01(3) pp. 1; 1988, Vol. 02(4) pp. 2; 1989, Vol. 03(1) pp. 4; 1990, Vol. 04(1) pp. 2; 1993, Vol. 07(4) pp. 4; 1997, Vol. 11(1) pp. 5.
drugs (fluoxetine) and, 1991, Vol. 05(4) pp. 1; 1993, Vol. 07(3) pp. 2.
drugs (naltrexone) and, 1996, Vol. 10(1) pp. 4
drugs (pentoxifyllin) and, 1997, Vol. 11(1) pp. 2
drugs (risperidone) and, 1994, Vol. 08(4) pp. 1; 1996, Vol. 10(2) pp. 2; 1998, Vol. 12(3) pp. 1.
drugs (SSRIs) and, 1997, Vol. 11(1) pp. 4
drugs (Trazadone) and, 1992, Vol. 06(1) pp. 5
drugs (venlafaxine) and, 2000, Vol. 14(2) pp. 4
familial patterns studies, 1989, Vol. 03(2) pp. 6; 1991, Vol. 05(2) pp. 4.
HCL and, 1998, Vol. 12(4) pp. 7
and immune system, 1987, Vol. 01(2) pp. 2; 1996, Vol. 10(4) pp. 2.
L-5HTP and, 1987, Vol. 01(4) pp. 7
and large neutral amino acids (LNAAs), 1996, Vol. 10(1) pp. 6
and metabolic disorders, 1987, Vol. 01(4) pp. 6
and obsessive-compulsive disorder, 1994, Vol. 08(3) pp. 4
phenols and, 1994, Vol. 08(1) pp. 4
and pituitary gland, 1987, Vol. 01(4) pp. 7; 1991, Vol. 05(2) pp. 5.
and R-THBP, 1987, Vol. 01(4) pp. 6; 1989, Vol. 03(2) pp. 4.
and Rett's, 1989, Vol. 03(2) pp. 4; 1990, Vol. 04(4) pp. 4; 1994, Vol. 08(4) pp. 4.
and secretin, 1998, Vol. 12(3) pp. 3
and self-injuring behaviors, 1993, Vol. 07(1) pp. 4
and sound sensitivity, 1991, Vol. 05(1) pp. 3
supplements (5-HTP) and, 1999, Vol. 13(1) pp. 2
supplements (calcium) and, 1995, Vol. 09(1) pp. 4
supplements (melatonin) and, 1992, Vol. 06(2) pp. 2; 1993, Vol. 07(3) pp. 4.
supplements (tryptophan) and, 1987, Vol. 01(4) pp. 6; 1996, Vol. 10(1) pp. 6; 1996, Vol. 10(4) pp. 6.
supplements (vitamin B6) and, 1997, Vol. 11(2) pp. 3
and synthesis of in autistics' brains, 1999, Vol. 13(3) pp. 7
and Tourette's, 1990, Vol. 04(3) pp. 5; 1991, Vol. 05(3) pp. 2.
transporter gene of, 1997, Vol. 11(2) pp. 2; 1997, Vol. 11(4) pp. 2; 2000, Vol. 14(1) pp. 1.
and violence, 1995, Vol. 09(1) pp. 4
and zinc, 2004, Vol. 18(2) pp. 5
Seroussi, Karyn, 2002, Vol. 16(1) pp. 3; 2002, Vol. 16(3) pp. 7.
Seroxat (paroxetine, Paxil), 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2.
sertraline (Zoloft), 1996, Vol. 10(4) pp. 2; 1998, Vol. 12(2) pp. 4; 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
service providers' directory. See resource guides
Serzone (nefrazadone), 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
Sesame Street, 1988, Vol. 02(2) pp. 2
Sessions, Jeff (U.S. Senator), 2004, Vol. 18(4) pp. 3
7-methylxanthine, 2000, Vol. 14(3) pp. 6
sex-specific disorders. See gender differences
sexual problems, 2001, Vol. 15(2) pp. 4; 2002, Vol. 16(4) pp. 6.
Seys, Daniel M., 1996, Vol. 10(4) pp. 1–2
Shade, Ruth, 1991, Vol. 05(1) pp. 7
Shah, Amitta, 1995, Vol. 09(2) pp. 6; 2000, Vol. 14(4) pp. 4.
Shane, Howard, 1994, Vol. 08(1) pp. 7
Shao, Yujun, 2002, Vol. 16(2) pp. 5
Shapiro, Lawrence, 1992, Vol. 06(3) pp. 4; 1996, Vol. 10(3) pp. 2.
Shattock, Paul, 1991, Vol. 05(4) pp. 1; 1992, Vol. 06(1) pp. 7; 1993, Vol. 07(1) pp. 4; 2002, Vol. 16(3) pp. 1.
Shavelle, Robert M., 1999, Vol. 13(4) pp. 2; 2002, Vol. 16(1) pp. 5.
Shaw, Philip, 2004, Vol. 18(2) pp. 2
Shaw, William, 1996, Vol. 10(2) pp. 1; 2002, Vol. 16(3) pp. 1.
Shea, Sarah, 2004, Vol. 18(4) pp. 4
Sheinkopf, Stephen J., 1998, Vol. 12(2) pp. 5; 1998, Vol. 12(3) pp. 7.
sheltered employment, 1990, Vol. 04(3) pp. 2
Shenoy, S., 2000, Vol. 14(3) pp. 5
Shepherd, Charles, 1993, Vol. 07(3) pp. 4
Sherman, ___
Sherman, Diane, 2001, Vol. 15(1) pp. 6
Sherman, Jeffrey, 1990, Vol. 04(1) pp. 2
Sherrill, Carrie M., 2000, Vol. 14(2) pp. 7
Shi, Limin, 2003, Vol. 17(2) pp. 2
Shields, Brooke (actress), 1989, Vol. 03(3) pp. 3
Shields, Donald, 1996, Vol. 10(1) pp. 5
Shilling, Paul D., 1997, Vol. 11(1) pp. 1
Shimka, Ann and Randy, 2001, Vol. 15(2) pp. 6
Shimoide, M., 1997, Vol. 11(1) pp. 1
Shprintzen velocardiofacial syndrome, 1996, Vol. 10(3) pp. 5
Shriqui, Christian L., 2002, Vol. 16(4) pp. 6
SIB. See self-injuring behaviors
SIBIS (self-injurious behavior intervention system)
aversives' controversy, 1990, Vol. 04(1) pp. 7; 1994, Vol. 08(2) pp. 4.
California Board of Education decision to allow, 1997, Vol. 11(4) pp. 1
cooperation improved, 1990, Vol. 04(2) pp. 6; 1995, Vol. 09(4) pp. 2.
description of, 1987, Vol. 01(3) pp. 1; 1988, Vol. 02(3) pp. 3; 1989, Vol. 03(4) pp. 3; 1995, Vol. 09(4) pp. 2; 1996, Vol. 10(4) pp. 2.
drugs and aversives compared, 1989, Vol. 03(4) pp. 1
and HSP 3012, 1996, Vol. 10(4) pp. 1–2
legislation for, 1996, Vol. 10(2) pp. 3
and non-aversives compared, 1990, Vol. 04(3) pp. 7
Sichel, Arthur G., 1996, Vol. 10(2) pp. 4
sick building syndrome, 2004, Vol. 18(4) pp. 7
Siege (Park), 1990, Vol. 04(1) pp. 7
Siegel, Bryna, 1987, Vol. 01(3) pp. 3; 1998, Vol. 12(2) pp. 5; 1998, Vol. 12(3) pp. 7.
Siever, Larry, 1997, Vol. 11(3) pp. 5
sign language
Silent Words/Forever Friends (Eastham and Eastham), 1992, Vol. 06(2) pp. 7; 1992, Vol. 06(3) pp. 3.
Silva, Susana C., 2004, Vol. 18(3) pp. 7
Silver, Archie A., 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(4) pp. 2.
Silver, Larry, 2000, Vol. 14(3) pp. 1
Simon, Nicole, 2004, Vol. 18(1) pp. 6
Simon-Soret, C., 1988, Vol. 02(3) pp. 4; 1990, Vol. 04(4) pp. 4.
Simpson, Richard L., 1992, Vol. 06(4) pp. 1
Simpson, Steve, 2000, Vol. 14(4) pp. 4
simultaneous communication, 1987, Vol. 01(3) pp. 5; 1996, Vol. 10(1) pp. 5.
Singh, Nirbhay N., 2003, Vol. 17(3) pp. 7
Singh, Vijendra K.
on anti-brain antibodies, 2004, Vol. 18(1) pp. 6
Fudenberg skeptic, 1990, Vol. 04(2) pp. 7
on major histocompatibility complex, 1996, Vol. 10(4) pp. 2
myelin basic protein defect report, 1993, Vol. 07(1) pp. 5; 2000, Vol. 14(4) pp. 1; 2002, Vol. 16(1) pp. 6; 2004, Vol. 18(4) pp. 4.
viruses and immunizations in autism, 1999, Vol. 13(1) pp. 4; 2003, Vol. 17(2) pp. 6.
single-dose vaccines, 2003, Vol. 17(3) pp. 7
Sirianni, Nicky, 1999, Vol. 13(1) pp. 6
Sjoholm, Bernt, 1988, Vol. 02(4) pp. 2
Sjoholm, Marianne, 1988, Vol. 02(4) pp. 2
skills training, 1987, Vol. 01(1) pp. 5; 1996, Vol. 10(2) pp. 5.
skin abnormalities, 1998, Vol. 12(1) pp. 4
skin disorders
and HUFA deficiency, 2000, Vol. 14(4) pp. 6
hypomelanosis of Ito, 1992, Vol. 06(1) pp. 4
from lamotrigine, 1998, Vol. 12(2) pp. 5
neurocutaneous disorders in autistics, 1998, Vol. 12(1) pp. 4
neurofibromatosis, 1988, Vol. 02(1) pp. 1
tuberous sclerosis, 1987, Vol. 01(2) pp. 4; 1989, Vol. 03(2) pp. 6.
Skinner, B. F., 1988, Vol. 02(3) pp. 6
Skuse, David, 2001, Vol. 15(1) pp. 5
slavery and required inclusion compared, 1993, Vol. 07(1) pp. 3
sleep difficulties. See also insomnia
and anxiety, 1998, Vol. 12(4) pp. 5
apnea, 1999, Vol. 13(3) pp. 1
behavior modification for, 1993, Vol. 07(3) pp. 5; 1997, Vol. 11(4) pp. 6; 1998, Vol. 12(4) pp. 5.
and behavior problems, 1993, Vol. 07(3) pp. 5; 1994, Vol. 08(3) pp. 1.
in catatonic autistics, 2000, Vol. 14(4) pp. 4
diets for, 1989, Vol. 03(3) pp. 4; 1999, Vol. 13(2) pp. 6.
drugs (bromacryptine) for, 1991, Vol. 05(1) pp. 7
drugs (lithium) for, 1989, Vol. 03(3) pp. 4
drugs (risperidone) for, 1997, Vol. 11(3) pp. 2; 2000, Vol. 14(1) pp. 5.
drugs (SSRIs) for, 1997, Vol. 11(2) pp. 4
5-HTP for, 1999, Vol. 13(1) pp. 2
and HUFA (highly unsaturated fatty acids) deficiency, 2000, Vol. 14(4) pp. 6
immunotherapy for, 1989, Vol. 03(4) pp. 2
L-carnitine for Rett's, 1999, Vol. 13(2) pp. 4
massage therapy for, 2002, Vol. 16(1) pp. 5
melatonin for, 1993, Vol. 07(3) pp. 4; 1994, Vol. 08(2) pp. 6; 1994, Vol. 08(3) pp. 1; 1999, Vol. 13(4) pp. 6.
neurofeedback therapy for, 2003, Vol. 17(1) pp. 2
and omega-3 fatty acid levels, 1999, Vol. 13(1) pp. 7; 2002, Vol. 16(2) pp. 4.
in Rett's Syndrome, 1991, Vol. 05(1) pp. 7
secretin for, 1998, Vol. 12(4) pp. 3; 1999, Vol. 13(1) pp. 3.
and self-injury, 1997, Vol. 11(4) pp. 5
substitute moms for, 1993, Vol. 07(4) pp. 5
from vaccines, 1999, Vol. 13(3) pp. 1
valerian for, 2003, Vol. 17(1) pp. 4
vitamin B6 for, 1991, Vol. 05(2) pp. 7; 1994, Vol. 08(2) pp. 6; 1994, Vol. 08(3) pp. 2.
Slotkin, Theodore A., 2004, Vol. 18(3) pp. 6
Slow-Mag-SEARLE, 1991, Vol. 05(3) pp. 2
slow viruses, 1989, Vol. 03(4) pp. 1–2
Sluyter, David, 1989, Vol. 03(1) pp. 1
small talk, 1991, Vol. 05(2) pp. 6
Smalley, Susan, 1989, Vol. 03(2) pp. 1
Smeeth, Liam, 2004, Vol. 18(3) pp. 1; 2004, Vol. 18(4) pp. 5.
Smith, Donald E. P., 1988, Vol. 02(2) pp. 5
Smith, Jeffrey, 1992, Vol. 06(2) pp. 6
Smith, Julia, 1989, Vol. 03(1) pp. 2
Smith, London, 1995, Vol. 09(1) pp. 1
Smith, Marcia Datlow
Smith, Marianne, 1990, Vol. 04(4) pp. 7
Smithells, Richard, 1989, Vol. 03(2) pp. 4
Smith,Tristram, 1993, Vol. 07(1) pp. 1; 1993, Vol. 07(2) pp. 5; 1996, Vol. 10(1) pp. 2; 1998, Vol. 12(1) pp. 1; 2000, Vol. 14(4) pp. 2.
Snelgrove, A., 1999, Vol. 13(1) pp. 7
Snodgrass, S. Robert, 1987, Vol. 01(3) pp. 2
Snoezelen rooms, 2001, Vol. 15(3) pp. 5
Snyder, Allan W., 1998, Vol. 12(3) pp. 6
Snyder, K.M., 1992, Vol. 06(4) pp. 3
sociability, 1991, Vol. 05(2) pp. 7; 1993, Vol. 07(1) pp. 7; 1994, Vol. 08(2) pp. 6; 1995, Vol. 09(2) pp. 7.
social communication disorder, 1991, Vol. 05(2) pp. 2
social deficits
ACTH for, 1992, Vol. 06(4) pp. 4
and albumin serum concentration, 2002, Vol. 16(4) pp. 4
autoimmunity in, 1999, Vol. 13(2) pp. 4
and beta-casomorphin, 1999, Vol. 13(2) pp. 1
brain abnormalities and, 1994, Vol. 08(2) pp. 1; 1998, Vol. 12(4) pp. 6; 2001, Vol. 15(3) pp. 4; 2001, Vol. 15(4) pp. 4; 2002, Vol. 16(4) pp. 4.
in catatonic autistics, 2000, Vol. 14(4) pp. 4
cognitive problems and, 1987, Vol. 01(4) pp. 1
cooperation, 1992, Vol. 06(3) pp. 6
DMG for, 1992, Vol. 06(2) pp. 6; 1992, Vol. 06(3) pp. 6; 1993, Vol. 07(3) pp. 6; 1994, Vol. 08(4) pp. 7; 1996, Vol. 10(3) pp. 7; 1997, Vol. 11(4) pp. 7; 1998, Vol. 12(1) pp. 7; 2001, Vol. 15(3) pp. 6.
drugs (anti-convulsant) for, 1994, Vol. 08(2) pp. 7
drugs (clomipramine) for, 1992, Vol. 06(4) pp. 5; 1993, Vol. 07(3) pp. 1; 1993, Vol. 07(4) pp. 1; 1996, Vol. 10(4) pp. 4; 1998, Vol. 12(1) pp. 4.
drugs (clonidine) for, 1992, Vol. 06(3) pp. 2
drugs (d-cycloserine) for, 2004, Vol. 18(4) pp. 5
drugs (eltoprazine) for, 1992, Vol. 06(2) pp. 2
drugs (fluoxetine) for, 1998, Vol. 12(3) pp. 4; 1998, Vol. 12(4) pp. 1; 1999, Vol. 13(2) pp. 2.
drugs (fluvoxamine) for, 1996, Vol. 10(4) pp. 7
drugs (lithium) for, 1989, Vol. 03(3) pp. 4
drugs (mecamylamine) for, 1998, Vol. 12(4) pp. 2
drugs (naltrexone) for, 1989, Vol. 03(3) pp. 1; 1995, Vol. 09(2) pp. 2; 1996, Vol. 10(3) pp. 6.
drugs (oxytocin) and, 1993, Vol. 07(4) pp. 4; 1996, Vol. 10(3) pp. 2; 1997, Vol. 11(4) pp. 7; 2001, Vol. 15(1) pp. 4; 2002, Vol. 16(4) pp. 5.
drugs (pentoxifylline) for, 1997, Vol. 11(1) pp. 1–2
drugs (Pepcid) for, 1999, Vol. 13(2) pp. 2
drugs (risperidone) for, 1997, Vol. 11(1) pp. 2; 1997, Vol. 11(2) pp. 6; 2000, Vol. 14(1) pp. 5; 2001, Vol. 15(2) pp. 4.
drugs (SSRIs) for, 1996, Vol. 10(4) pp. 2
drugs (venlafaxine) for, 2000, Vol. 14(2) pp. 4
ENZYMAID for, 2002, Vol. 16(2) pp. 4
Epsom salts for, 2001, Vol. 15(3) pp. 6
and eye contact, 1993, Vol. 07(2) pp. 4
and eye movement abnormalities, 1997, Vol. 11(3) pp. 5
in families of autistics, 1998, Vol. 12(3) pp. 2
fish oil for, 2000, Vol. 14(4) pp. 6
and gene suppression, 1993, Vol. 07(1) pp. 5
gluten-free diet for, 1999, Vol. 13(2) pp. 6
in high-functioning autistics, 1988, Vol. 02(3) pp. 4
and IgG (immune gamma globulin), 2002, Vol. 16(4) pp. 4
from influenza in-utero, 2003, Vol. 17(2) pp. 2
intravenous gamma globulin therapy helpful for, 1998, Vol. 12(2) pp. 1
L-carnosine for, 2003, Vol. 17(1) pp. 1
magnesium for, 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(4) pp. 1; 1994, Vol. 08(3) pp. 6; 1994, Vol. 08(4) pp. 7; 1998, Vol. 12(1) pp. 7; 2001, Vol. 15(3) pp. 6.
and mercury poisoning, 2000, Vol. 14(2) pp. 7
Mind Reading computer program for, 2003, Vol. 17(2) pp. 5
and onset time, 1994, Vol. 08(4) pp. 4
over-questioning, 1996, Vol. 10(2) pp. 5
PARLE (Portable Affect Recognition Learning Environment) for, 2003, Vol. 17(3) pp. 5
perceptual abnormalities, 1995, Vol. 09(4) pp. 5; 2003, Vol. 17(2) pp. 6.
R-THBP for, 1997, Vol. 11(4) pp. 4
role confusion, 1991, Vol. 05(4) pp. 7
schizophrenia's negative symptoms compared, 1997, Vol. 11(3) pp. 4
secretin for, 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(4) pp. 3; 2000, Vol. 14(1) pp. 7; 2001, Vol. 15(4) pp. 1.
self-management for, 1992, Vol. 06(4) pp. 5
sensory integration therapy for, 1997, Vol. 11(4) pp. 5; 1999, Vol. 13(2) pp. 5.
in siblings of autistics, 1997, Vol. 11(2) pp. 4
social scripts for new readers, 1998, Vol. 12(3) pp. 5
socio-emotional deficits, 1990, Vol. 04(3) pp. 4
and tetanus neurotoxins, 1998, Vol. 12(4) pp. 6
theory of mind and, 1987, Vol. 01(4) pp. 1; 1990, Vol. 04(2) pp. 2; 1996, Vol. 10(1) pp. 6; 1997, Vol. 11(1) pp. 7.
and TSP (total serum protein) serum concentrations, 2002, Vol. 16(4) pp. 4
two-trainer therapy model for, 2001, Vol. 15(1) pp. 6
video modeling for, 2003, Vol. 17(1) pp. 5
vitamin B6 for, 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(4) pp. 1; 1994, Vol. 08(3) pp. 6; 1994, Vol. 08(4) pp. 7; 1998, Vol. 12(1) pp. 7; 2001, Vol. 15(3) pp. 6.
vitamin C for, 1998, Vol. 12(2) pp. 3; 2001, Vol. 15(3) pp. 6.
withdrawal, 1990, Vol. 04(4) pp. 4; 1993, Vol. 07(3) pp. 2; 2002, Vol. 16(4) pp. 4.
and Y chromosome, 1998, Vol. 12(4) pp. 4
social peptides, 1993, Vol. 07(4) pp. 4
social phobias, 1999, Vol. 13(2) pp. 6
Social Reciprocity Scale (SRS), 2002, Vol. 16(2) pp. 4
social skills
affection training, 1988, Vol. 02(4) pp. 5
animal therapy for, 1989, Vol. 03(4) pp. 2
for Asperger kids, 1995, Vol. 09(2) pp. 6
control of choice in interactions, 1988, Vol. 02(1) pp. 7
conversational coaching, 1988, Vol. 02(1) pp. 6; 1988, Vol. 02(3) pp. 5.
cueing, 1988, Vol. 02(4) pp. 5
early intervention programs for, 2002, Vol. 16(3) pp. 5
employment as incentive, 1990, Vol. 04(3) pp. 6
eye contact, 1993, Vol. 07(2) pp. 4; 1993, Vol. 07(3) pp. 6; 2002, Vol. 16(4) pp. 2.
fixation channeling, 1999, Vol. 13(2) pp. 5
imagery, 1988, Vol. 02(4) pp. 5
joint attention, 2002, Vol. 16(4) pp. 2
KidTalk computer program for, 2002, Vol. 16(1) pp. 5
for men with Asperger's and high-functioning autism, 1999, Vol. 13(4) pp. 5
PECS (Picture Exchange Communication Skills) for, 2002, Vol. 16(3) pp. 5; 2002, Vol. 16(4) pp. 2.
peer tutors for, 1988, Vol. 02(1) pp. 7; 1994, Vol. 08(4) pp. 6.
pivotal response training for, 1994, Vol. 08(1) pp. 5
play, 1988, Vol. 02(1) pp. 7; 1988, Vol. 02(2) pp. 6; 1989, Vol. 03(3) pp. 5; 1991, Vol. 05(4) pp. 5; 2002, Vol. 16(4) pp. 2.
PLAY Project for, 2003, Vol. 17(2) pp. 5
prompts compared, 1988, Vol. 02(1) pp. 7
self-management for, 1992, Vol. 06(4) pp. 5
sensory integration training for, 1991, Vol. 05(2) pp. 6; 1999, Vol. 13(2) pp. 5.
sign language for special friends, 1990, Vol. 04(1) pp. 5
social stories for, 1993, Vol. 07(2) pp. 5
special friends for, 1990, Vol. 04(1) pp. 5
spontaneous communication for, 1988, Vol. 02(1) pp. 6; 1994, Vol. 08(4) pp. 6.
training for Asperger's children, 1995, Vol. 09(2) pp. 6
virtual reality for teaching, 2002, Vol. 16(3) pp. 5
vitamin B6 for, 1993, Vol. 07(1) pp. 7
workplace training in, 1994, Vol. 08(4) pp. 6
social stories, 1993, Vol. 07(2) pp. 5; 2002, Vol. 16(2) pp. 6.
social supports, 1991, Vol. 05(3) pp. 7
socialization, 1998, Vol. 12(2) pp. 3
Sockolow, R., 2000, Vol. 14(3) pp. 6
sodium fluoride, 1998, Vol. 12(4) pp. 5
sodium silocofluoride, 1998, Vol. 12(4) pp. 5
sodium valproate (divalproex sodium, Depakote), 2000, Vol. 14(2) pp. 5; 2001, Vol. 15(3) pp. 5.
software programs. See computer programs
Sogame, Shiro, 1997, Vol. 11(1) pp. 1; 1997, Vol. 11(2) pp. 7.
"Soles of the Feet" meditation, 2003, Vol. 17(3) pp. 7
Solomon, Rick, 2003, Vol. 17(2) pp. 5
Solving the Puzzle of Your Hard-To-Raise Child (Crook), 1989, Vol. 03(2) pp. 3; 2002, Vol. 16(3) pp. 7.
somatosensory cortex, 2004, Vol. 18(3) pp. 6
Sonia Shankman Orthogenic School, 1990, Vol. 04(2) pp. 1; 1990, Vol. 04(4) pp. 6.
Sotos syndrome, 1990, Vol. 04(4) pp. 5
Sound of a Miracle (Stehli), 1990, Vol. 04(4) pp. 6; 1991, Vol. 05(1) pp. 3; 1992, Vol. 06(2) pp. 1; 2000, Vol. 14(4) pp. 3.
sound sensitivity. See also Berard
and aspartame, 1992, Vol. 06(2) pp. 4; 1997, Vol. 11(4) pp. 2.
auditory integration therapy for, 1991, Vol. 05(1) pp. 3
auditory integration training for, 1999, Vol. 13(S) pp.
Berard AIT device, 1993, Vol. 07(3) pp. 2
drugs for, 1991, Vol. 05(1) pp. 3
headsets for, 2002, Vol. 16(1) pp. 7; 2002, Vol. 16(3) pp. 7.
magnesium for, 1992, Vol. 06(4) pp. 6
and mercury poisoning, 2000, Vol. 14(2) pp. 7; 2000, Vol. 14(3) pp. 1.
secretin for, 1998, Vol. 12(3) pp. 3
and seizures, 2001, Vol. 15(3) pp. 4
supplements for, 1991, Vol. 05(1) pp. 3; 1991, Vol. 05(3) pp. 2; 1992, Vol. 06(4) pp. 6; 1994, Vol. 08(1) pp. 7; 1998, Vol. 12(3) pp. 7; 2002, Vol. 16(2) pp. 2.
Tomatis Listening Centers, 1990, Vol. 04(4) pp. 3; 1991, Vol. 05(3) pp. 2.
treatments for, 1990, Vol. 04(4) pp. 3
South Carolina, Medical University, 1989, Vol. 03(4) pp. 1–3
South Caroline Autism Project, 1998, Vol. 12(3) pp. 4
South West Autism Programme (SWAP), 2002, Vol. 16(3) pp. 5
Soya-Kaas Mozzarella, 2000, Vol. 14(3) pp. 6
Spanish version of Mercury Detoxification Protocol, 2001, Vol. 15(3) pp. 4
spatial working memory, 2001, Vol. 15(1) pp. 6
special friends, 1990, Vol. 04(1) pp. 5
Specific Carbohydrate Diet (SCD), 2004, Vol. 18(3) pp. 3; 2004, Vol. 18(4) pp. 2.
specific language impairment (SLI), 2000, Vol. 14(3) pp. 7
specific requests, 2000, Vol. 14(4) pp. 4
SPECT (single photon emission tomography), 1992, Vol. 06(4) pp. 4
speech problems, 1992, Vol. 06(4) pp. 6. See also communication problems, language disorders
ABA (Applied Behavior Analysis) for (See Applied Behavior Analysis)
and academics, 1992, Vol. 06(3) pp. 4
in ADD and Fragile X compared, 1988, Vol. 02(2) pp. 5
brain hemisphere abnormalities, 1987, Vol. 01(1) pp. 4
calcium for, 1990, Vol. 04(1) pp. 2
cod liver oil for, 2000, Vol. 14(2) pp. 7
computerized feedback for, 1999, Vol. 13(3) pp. 6; 2000, Vol. 14(4) pp. 5.
from creatine transporter gene defect, 2003, Vol. 17(3) pp. 4
DMG for (See under DMG)
drugs (cerebrolysin) for, 2003, Vol. 17(3) pp. 5
drugs (clomipramine) for, 1993, Vol. 07(3) pp. 1
drugs (fluoxetine) for, 1998, Vol. 12(3) pp. 4; 1998, Vol. 12(4) pp. 1.
drugs (galantamine) for, 2002, Vol. 16(4) pp. 5
drugs (lithium) for, 1988, Vol. 02(1) pp. 1; 1989, Vol. 03(3) pp. 4.
early intervention for, 1998, Vol. 12(1) pp. 2; 1999, Vol. 13(4) pp. 1; 2004, Vol. 18(3) pp. 5.
echolalia, 1987, Vol. 01(3) pp. 5; 1994, Vol. 08(4) pp. 5; 1996, Vol. 10(3) pp. 6.
from Epstein-Barr infection, 2001, Vol. 15(1) pp. 4
facilitated communication for, 1990, Vol. 04(4) pp. 1–2
in Fragile X and ADD compared, 1988, Vol. 02(2) pp. 5
from frontal lobe seizures, 1992, Vol. 06(1) pp. 4; 1993, Vol. 07(1) pp. 4.
IBM SpeechViewer for, 1999, Vol. 13(3) pp. 6
and imitation skills, 2002, Vol. 16(4) pp. 2
inappropriate speech, 1998, Vol. 12(3) pp. 4; 2002, Vol. 16(4) pp. 5.
intravenous gamma globulin therapy helpful for, 1998, Vol. 12(2) pp. 1–2
in Landau-Kleffner syndrome, 1991, Vol. 05(1) pp. 2
from low-frequency hearing loss, 2003, Vol. 17(3) pp. 4
magnesium for, 1994, Vol. 08(1) pp. 7; 1994, Vol. 08(2) pp. 6; 1996, Vol. 10(3) pp. 7; 1998, Vol. 12(1) pp. 7; 1998, Vol. 12(3) pp. 7; 2001, Vol. 15(3) pp. 6.
and mercury poisoning, 2000, Vol. 14(3) pp. 1
mirror neuron deficit and, 2001, Vol. 15(3) pp. 4
Natural Language Paradigm (NLP) for, 1989, Vol. 03(2) pp. 5
neurofeedback therapy for, 2003, Vol. 17(1) pp. 2
and onset time, 1994, Vol. 08(4) pp. 4; 1996, Vol. 10(2) pp. 7.
PECS (Picture-Exchange Communication) for, 1995, Vol. 09(3) pp. 5
secretin for, 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(3) pp. 3; 1998, Vol. 12(4) pp. 3; 1999, Vol. 13(1) pp. 3; 1999, Vol. 13(4) pp. 7.
sensory integration therapy for, 1990, Vol. 04(4) pp. 5; 1991, Vol. 05(2) pp. 6; 1999, Vol. 13(2) pp. 5.
and serotonin, 1987, Vol. 01(4) pp. 6
sex-specific differences, 1987, Vol. 01(4) pp. 6
shaping in speech training, 1989, Vol. 03(1) pp. 5
sign language for, 1987, Vol. 01(3) pp. 5
speech loss prognosis, 1987, Vol. 01(4) pp. 6
stereotyped speech, 1990, Vol. 04(2) pp. 2
stimulus overselectivity, 1988, Vol. 02(1) pp. 5; 1994, Vol. 08(4) pp. 5.
"talking head" for, 2001, Vol. 15(4) pp. 5
and tetanus neurotoxins, 1998, Vol. 12(4) pp. 6
and thimerosol, 2003, Vol. 17(4) pp. 2
training techniques compared, 1989, Vol. 03(1) pp. 5
videos for conversation skills, 1990, Vol. 04(1) pp. 5
vitamin B6 for, 1993, Vol. 07(3) pp. 6; 1994, Vol. 08(1) pp. 7; 1994, Vol. 08(2) pp. 6; 1996, Vol. 10(2) pp. 1; 1996, Vol. 10(3) pp. 7; 1998, Vol. 12(1) pp. 7; 1998, Vol. 12(3) pp. 7; 2001, Vol. 15(3) pp. 6; 2002, Vol. 16(2) pp. 2.
vitamin C for, 2001, Vol. 15(3) pp. 6
vocabulary, 2000, Vol. 14(4) pp. 5; 2001, Vol. 15(3) pp. 6; 2002, Vol. 16(2) pp. 4; 2002, Vol. 16(3) pp. 6.
Spence, M.A., 1989, Vol. 03(2) pp. 6
Sperber, Dan, 1990, Vol. 04(2) pp. 2
Sperling, Michael R., 1996, Vol. 10(3) pp. 5
Spiker, Donna, 1992, Vol. 06(2) pp. 1; 1993, Vol. 07(2) pp. 2; 1994, Vol. 08(1) pp. 4; 2000, Vol. 14(1) pp. 1.
Spirolactone, 1998, Vol. 12(4) pp. 7
Spitzer, Walter O., 2001, Vol. 15(3) pp. 1; 2002, Vol. 16(2) pp. 1.
spontaneous communication, 1988, Vol. 02(1) pp. 6; 1989, Vol. 03(4) pp. 2; 1994, Vol. 08(4) pp. 5.
Sposato, Beth, 1989, Vol. 03(4) pp. 7
squalene, 2003, Vol. 17(3) pp. 5
squeeze machine, 1987, Vol. 01(2) pp. 5; 1987, Vol. 01(3) pp. 3; 1987, Vol. 01(4) pp. 2; 1995, Vol. 09(3) pp. 6; 1998, Vol. 12(3) pp. 1.
Srebrnik, Avigdor, 1998, Vol. 12(1) pp. 4
Sreekumaran, E., 2003, Vol. 17(1) pp. 4
SRIs (serotonin reuptake inhibitors), 1998, Vol. 12(2) pp. 6
SSEP (Short latency somatosensory evoked potentials) test, 1987, Vol. 01(4) pp. 7
SSRIs. See selective serotonin reputake inhibitors (SSRIs)
St. John's wort, 2001, Vol. 15(1) pp. 5; 2002, Vol. 16(4) pp. 5.
St. Nicholas Hospital, 1991, Vol. 05(1) pp. 6; 1991, Vol. 05(2) pp. 6.
Stahmer, Aubyn, 1995, Vol. 09(3) pp. 5
Stajich, Gregory, 2000, Vol. 14(3) pp. 1
Staley, Louise, 1994, Vol. 08(1) pp. 4
standard prompting hierarchy, 1991, Vol. 05(3) pp. 5
staring spells, 1988, Vol. 02(1) pp. 1
Starobrat-Hermelin, Barbara, 1998, Vol. 12(2) pp. 4
startle response, 2003, Vol. 17(2) pp. 2
state agencies
ARC of California, 1997, Vol. 11(1) pp. 3
California Department of Developmental Services (DDS), 1997, Vol. 11(1) pp. 3; 2001, Vol. 15(1) pp. 2; 2001, Vol. 15(3) pp. 2; 2004, Vol. 18(2) pp. 9.
California State Board of Education, 1997, Vol. 11(4) pp. 1
Maryland Special Education, 1999, Vol. 13(4) pp. 2
Statement on Punishment, 1988, Vol. 02(3) pp. 6
Steele, Margaret, 1997, Vol. 11(1) pp. 2; 1997, Vol. 11(2) pp. 7.
Stefanatos, Gerry A., 1991, Vol. 05(4) pp. 6; 1992, Vol. 06(1) pp. 6; 1994, Vol. 08(2) pp. 6; 1995, Vol. 09(3) pp. 1; 1995, Vol. 09(4) pp. 3.
Steffenburg, S., 1989, Vol. 03(4) pp. 4
Stehli, Annabel, 1990, Vol. 04(4) pp. 6; 1992, Vol. 06(2) pp. 1; 2000, Vol. 14(4) pp. 3.
Steinemann, Thomas L., 1998, Vol. 12(3) pp. 4
Steingard, Ronald, 1989, Vol. 03(3) pp. 4
Steinhausen, H.C., 1989, Vol. 03(2) pp. 1
Stenbom, Y., 1998, Vol. 12(2) pp. 5
stereotypies. See also self-stimulating behaviors
in autistics' inside report, 1991, Vol. 05(4) pp. 7
brain abnormalities, 1995, Vol. 09(3) pp. 4; 2001, Vol. 15(4) pp. 4.
brief movement restriction for, 1991, Vol. 05(4) pp. 5
causes discussed, 1988, Vol. 02(2) pp. 2
as cyclical, 1995, Vol. 09(1) pp. 4
drug symptoms compared to, 1989, Vol. 03(4) pp. 4
drugs (buspirone) for, 1990, Vol. 04(3) pp. 7; 1991, Vol. 05(4) pp. 4; 1996, Vol. 10(1) pp. 4.
drugs (clomipramine) for, 1993, Vol. 07(3) pp. 1; 1993, Vol. 07(4) pp. 1; 1996, Vol. 10(4) pp. 4.
drugs (fluoxetine) for, 1991, Vol. 05(2) pp. 4; 1991, Vol. 05(4) pp. 1; 1998, Vol. 12(3) pp. 4; 1998, Vol. 12(4) pp. 1.
drugs (naltrexone) for, 1989, Vol. 03(3) pp. 1; 1992, Vol. 06(2) pp. 2.
drugs (oxytocin) for, 1993, Vol. 07(4) pp. 4
drugs(risperidone) for, 1994, Vol. 08(4) pp. 1
exercise for, 1994, Vol. 08(1) pp. 4–5
in families of autistics, 1998, Vol. 12(3) pp. 2
focusing training for, 1998, Vol. 12(1) pp. 2
Gentle Teaching and, 1989, Vol. 03(2) pp. 2
and gluten, 1999, Vol. 13(2) pp. 6
massage therapy for, 2002, Vol. 16(1) pp. 5
and opioids of the brain, 1987, Vol. 01(4) pp. 4; 1990, Vol. 04(4) pp. 4; 1991, Vol. 05(4) pp. 2.
and peptides, 1991, Vol. 05(4) pp. 2
positive practice overcorrection for, 2001, Vol. 15(1) pp. 5
in Rett's males, 1989, Vol. 03(1) pp. 4
self-monitoring for, 1997, Vol. 11(2) pp. 5
sensory integration therapy for, 1997, Vol. 11(4) pp. 5
sensory stimulation for, 1995, Vol. 09(2) pp. 5
Snoezelen room for, 2001, Vol. 15(3) pp. 5
and tetanus neurotoxins, 1998, Vol. 12(4) pp. 1
vitamin C for, 1992, Vol. 06(1) pp. 4
Sterman, M. Barry, 1996, Vol. 10(2) pp. 4
Sternglass, Ernest, 1989, Vol. 03(4) pp. 5
steroids. See corticosteroids
Steuerwald, U., 2000, Vol. 14(3) pp. 2
Stevens, L. J., 1999, Vol. 13(1) pp. 7
Stewart, Gary R., 1994, Vol. 08(4) pp. 7
Stewart, Jane G., 1999, Vol. 13(4) pp. 6
Stewart, K. B., 1999, Vol. 13(2) pp. 5
Stewart, Phyllis, 1990, Vol. 04(1) pp. 7
stimming. See self-stimulating behaviors
stimulation, 1988, Vol. 02(2) pp. 2
stimulus overselectivity, 1994, Vol. 08(4) pp. 5
Stittgen, Susan, 1990, Vol. 04(4) pp. 7
Stoiber, Suzanne A., 2001, Vol. 15(3) pp. 1
Stokke-Johnsen, Ketil and Sarah, 1995, Vol. 09(4) pp. 6
Stoll, Andrew, 1999, Vol. 13(1) pp. 7; 2002, Vol. 16(3) pp. 1.
Stone, Irwin, 1998, Vol. 12(2) pp. 3
stoppage, 2001, Vol. 15(4) pp. 5
Storch, Laura, 1993, Vol. 07(1) pp. 7; 1994, Vol. 08(1) pp. 5.
Storch, Mark, 1993, Vol. 07(1) pp. 7
Stordy, B. Jacqueline, 2000, Vol. 14(4) pp. 6
Stowell, Philip, 2002, Vol. 16(1) pp. 6
strabismus
in boys and girls compared, 1999, Vol. 13(3) pp. 6
in Fragile X, 1991, Vol. 05(4) pp. 4
and motor difficulties, 1999, Vol. 13(3) pp. 6
prism lenses for, 1998, Vol. 12(3) pp. 6; 1999, Vol. 13(3) pp. 6.
transitional lenses for, 1999, Vol. 13(3) pp. 6
Strain, Philip, 1988, Vol. 02(1) pp. 7
strategy, rule-based, 1987, Vol. 01(1) pp. 2
Stratton, Kathleen, 1995, Vol. 09(1) pp. 1
Strauss, David, 1996, Vol. 10(4) pp. 1; 1997, Vol. 11(1) pp. 3; 1999, Vol. 13(4) pp. 1; 2002, Vol. 16(1) pp. 5.
Strauts, Ziguris, 1994, Vol. 08(1) pp. 5; 1995, Vol. 09(4) pp. 7.
strep
and obsessive compulsive disorders, 1996, Vol. 10(3) pp. 1; 1997, Vol. 11(2) pp. 2; 1999, Vol. 13(1) pp. 5; 1999, Vol. 13(3) pp. 7; 2000, Vol. 14(2) pp. 4; 2002, Vol. 16(1) pp. 4.
and PANDAS (pediatric neurospsychiatric disorders), 1998, Vol. 12(2) pp. 2; 1999, Vol. 13(1) pp. 5; 1999, Vol. 13(3) pp. 7.
and tic disorders, 1997, Vol. 11(2) pp. 2; 1999, Vol. 13(1) pp. 5; 2002, Vol. 16(1) pp. 4.
Streptococcus pneumoniae, 1997, Vol. 11(1) pp. 6; 1998, Vol. 12(4) pp. 4.
stress, 2001, Vol. 15(4) pp. 7
Strick, Peter, L., 1996, Vol. 10(1) pp. 4
Strickland, Dorothy, 1997, Vol. 11(1) pp. 5
strokes, 2003, Vol. 17(1) pp. 6
Stubbs, E. Gene
Sturmey, P., 1988, Vol. 02(3) pp. 5
Styka, Sandra, 2004, Vol. 18(3) pp. 6
Subcommitee on Human Rights and Wellness, 2003, Vol. 17(2) pp. 1–2
subcortical regions of brain, 2001, Vol. 15(4) pp. 4
substance abuse, 1991, Vol. 05(3) pp. 1; 1992, Vol. 06(2) pp. 4.
substantia nigra, 1994, Vol. 08(4) pp. 4
substitute moms, 1993, Vol. 07(4) pp. 5
subtypes of autism, 1993, Vol. 07(2) pp. 3; 1999, Vol. 13(2) pp. 2; 2003, Vol. 17(1) pp. 6.
sucrase, 2001, Vol. 15(4) pp. 2
sudden infant death, 1995, Vol. 09(1) pp. 1; 1998, Vol. 12(1) pp. 3.
Sugai, George, 1987, Vol. 01(2) pp. 5
Sugiyama, N., 1998, Vol. 12(1) pp. 4
Sugiyama, Toshiro, 1989, Vol. 03(2) pp. 1
suicide
sulfation, 2002, Vol. 16(1) pp. 7; 2003, Vol. 17(2) pp. 7.
Sullivan, Bill, 1989, Vol. 03(1) pp. 3
Sullivan, Joseph, 1989, Vol. 03(1) pp. 3
Sullivan, Ruth, 1989, Vol. 03(1) pp. 3
sulphate intolerances, 1994, Vol. 08(1) pp. 4
sulphur, 2001, Vol. 15(3) pp. 6
sulpiride, 1989, Vol. 03(2) pp. 4
Summers, Jane, 1993, Vol. 07(3) pp. 5
Sun, Zhongjie, 1999, Vol. 13(2) pp. 1
Sundram, Clarence, 1993, Vol. 07(4) pp. 3
Super Nu-Thera, 1993, Vol. 07(3) pp. 6; 1997, Vol. 11(1) pp. 6; 1997, Vol. 11(4) pp. 1.
superior olive abnormalities, 1997, Vol. 11(3) pp. 1
superior temporal sulcus (STS), 2003, Vol. 17(2) pp. 6
supervision, random, 1987, Vol. 01(2) pp. 5
supplements
and ABA (Applied Behavior Analysis) as complementary, 1999, Vol. 13(3) pp. 3
for ADHD (attention deficit hyperactivity disorder), 1995, Vol. 09(1) pp. 3; 2001, Vol. 15(2) pp. 6; 2003, Vol. 17(4) pp. 7.
agnus castus, 2001, Vol. 15(1) pp. 4
antioxidants as antidote for chloral hydrate, 1991, Vol. 05(1) pp. 4
arginine pyroglutamate, 1995, Vol. 09(1) pp. 6
for behaviors, 1987, Vol. 01(4) pp. 3; 1988, Vol. 02(4) pp. 2; 1992, Vol. 06(1) pp. 4. See also individual supplements)
beta carotene, 1995, Vol. 09(4) pp. 5
betaine, 2004, Vol. 18(4) pp. 1
bigotry about, 2000, Vol. 14(3) pp. 3
for bipolar disorder, 2000, Vol. 14(4) pp. 3; 2002, Vol. 16(1) pp. 2; 2002, Vol. 16(4) pp. 4.
for birth defect prevention, 1989, Vol. 03(2) pp. 4; 1995, Vol. 09(1) pp. 4; 1997, Vol. 11(2) pp. 2.
calcium, 1990, Vol. 04(1) pp. 2; 1990, Vol. 04(2) pp. 3; 1995, Vol. 09(1) pp. 4; 1998, Vol. 12(3) pp. 6; 2002, Vol. 16(2) pp. 7.
chaste tree berry, 2001, Vol. 15(1) pp. 4
cod liver oil, 2000, Vol. 14(1) pp. 6; 2000, Vol. 14(2) pp. 7; 2002, Vol. 16(3) pp. 7.
coenzyme Q10, 1999, Vol. 13(4) pp. 4
for coprophragia, 2001, Vol. 15(1) pp. 7
creatine, 1999, Vol. 13(3) pp. 4; 2003, Vol. 17(3) pp. 4.
DHA, 1999, Vol. 13(1) pp. 7; 2000, Vol. 14(2) pp. 6.
DMG (See DMG)
and early intervention, 1998, Vol. 12(1) pp. 2
eicosapentaenoic acid (EPA), 1999, Vol. 13(1) pp. 7; 2002, Vol. 16(3) pp. 7; 2003, Vol. 17(4) pp. 2.
essential fatty acid therapy, 1990, Vol. 04(1) pp. 2; 1999, Vol. 13(1) pp. 7; 2003, Vol. 17(4) pp. 2.
FDA and (See FDA)
fenfluramine compared to, 1990, Vol. 04(2) pp. 4; 1991, Vol. 05(1) pp. 3.
fish oil, 1999, Vol. 13(1) pp. 7; 2000, Vol. 14(4) pp. 6.
5-HTP, 1999, Vol. 13(1) pp. 2
folate, 2003, Vol. 17(1) pp. 5
folic acid (See folic acid)
folinic acid, 2004, Vol. 18(4) pp. 1
for Fragile X, 1987, Vol. 01(1) pp. 4; 1989, Vol. 03(2) pp. 2; 1990, Vol. 04(1) pp. 2; 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(2) pp. 4; 1995, Vol. 09(4) pp. 3.
funding needed on, 1997, Vol. 11(2) pp. 3
green tea, 2002, Vol. 16(4) pp. 5
and haloperidol (Haldol), 1988, Vol. 02(3) pp. 4; 1992, Vol. 06(1) pp. 4; 1992, Vol. 06(2) pp. 2.
HUFAs (highly unsaturated fatty acids), 2000, Vol. 14(4) pp. 6; 2002, Vol. 16(1) pp. 4.
and immune system, 1993, Vol. 07(4) pp. 6; 2000, Vol. 14(1) pp. 6.
inositol, 1997, Vol. 11(2) pp. 1–2
iron overload, 2001, Vol. 15(3) pp. 6
kava, 2000, Vol. 14(2) pp. 4
L-carnitine, 1996, Vol. 10(3) pp. 4; 1999, Vol. 13(2) pp. 4.
L-carnosine, 2003, Vol. 17(1) pp. 1
magnesium (See magnesium)
melatonin (See melatonin)
methylcobalamin, 2004, Vol. 18(4) pp. 1
methylphenidate (Ritalin) compared to, 2003, Vol. 17(4) pp. 7
milk of magnesia, 2003, Vol. 17(1) pp. 7
niacin, 1999, Vol. 13(4) pp. 4
for obsessive behaviors, 2002, Vol. 16(4) pp. 4
for obsessive-compulsive disorder, 2002, Vol. 16(4) pp. 4
omega-3-fatty acids, 1999, Vol. 13(1) pp. 7; 2000, Vol. 14(4) pp. 6; 2002, Vol. 16(2) pp. 4; 2002, Vol. 16(3) pp. 4; 2003, Vol. 17(4) pp. 2.
pangamic acid (vitamin B15), 1990, Vol. 04(2) pp. 3
for PDD (pervasive developmental disorder), 2002, Vol. 16(4) pp. 4
peptidase, 2000, Vol. 14(1) pp. 6
for pica, 2001, Vol. 15(1) pp. 7
piracetam, 1995, Vol. 09(1) pp. 6; 1996, Vol. 10(2) pp. 7.
PUFA (omega-3 polyunsaturated fatty acid) spread for seizures, 2002, Vol. 16(3) pp. 4
S.72 1988, Vol. 02(3) pp. 9
selenium, 2002, Vol. 16(3) pp. 7
SerenAid, 2000, Vol. 14(1) pp. 6
and SSRIs compared, 1999, Vol. 13(4) pp. 3; 2000, Vol. 14(4) pp. 4.
St. John's wort, 2001, Vol. 15(1) pp. 5; 2002, Vol. 16(4) pp. 5.
Super Nu-Thera, 1993, Vol. 07(3) pp. 6; 1997, Vol. 11(1) pp. 6; 1997, Vol. 11(4) pp. 1.
Tarvil, 2003, Vol. 17(3) pp. 6
tryptophan (See tryptophan)
TTFD (thiamine tetrahydrofurfuryl disulfide), 2002, Vol. 16(3) pp. 4
for vaccinations, 1999, Vol. 13(1) pp. 7; 2000, Vol. 14(1) pp. 5; 2001, Vol. 15(2) pp. 3; 2002, Vol. 16(4) pp. 3.
valerian, 2003, Vol. 17(1) pp. 4
vitamin A, 1994, Vol. 08(4) pp. 1; 1995, Vol. 09(4) pp. 5; 1998, Vol. 12(3) pp. 4; 2000, Vol. 14(1) pp. 5; 2002, Vol. 16(3) pp. 7.
vitamin B1, 1990, Vol. 04(1) pp. 2; 2002, Vol. 16(3) pp. 4.
vitamin B 1992, Vol. 06(S) pp.
vitamin B 1989, Vol. 03(n) pp. ,; 1998, Vol. 12(3) pp. 7.
vitamin B1 1991, Vol. 05(2) pp. 3
vitamin C (See vitamin C)
vitamin D, 1998, Vol. 12(3) pp. 4
vitamin E (See vitamin E)
vitamin therapy in general, 1987, Vol. 01(4) pp. 3; 1997, Vol. 11(3) pp. 1.
supported employment, 1990, Vol. 04(3) pp. 2
surgery
anesthesia for autistics, 1999, Vol. 13(3) pp. 5
for ear infections, 1994, Vol. 08(4) pp. 1
gastrostomy, 1997, Vol. 11(3) pp. 4
for Landau-Kleffner syndrome, 1991, Vol. 05(1) pp. 1; 1991, Vol. 05(4) pp. 6; 1992, Vol. 06(1) pp. 6; 1995, Vol. 09(2) pp. 2; 1996, Vol. 10(2) pp. 1.
for seizure disorders, 1991, Vol. 05(1) pp. 2; 1991, Vol. 05(4) pp. 6; 1992, Vol. 06(1) pp. 6; 1996, Vol. 10(2) pp. 7; 1996, Vol. 10(3) pp. 5; 1997, Vol. 11(3) pp. 4.
SSRIs and bleeding, 2004, Vol. 18(1) pp. 4
Susan Powter Show (TV show), 1995, Vol. 09(1) pp. 1
Susman, Edward, 1996, Vol. 10(3) pp. 1
Susser, Ezra S.
Sutherland, Grant, 1991, Vol. 05(2) pp. 1–2
Sutton, Linda G., 1998, Vol. 12(4) pp. 7
Suzuki, Hisaharu, 1991, Vol. 05(1) pp. 7
Suzuki, M., 1997, Vol. 11(1) pp. 2
Svennerholm, L., 1987, Vol. 01(4) pp. 4
Sverd, Jeffrey, 1991, Vol. 05(3) pp. 1
swearing, 1994, Vol. 08(2) pp. 5
Swedo, Susan E., 1999, Vol. 13(3) pp. 7
Sweeten, Thayne L., 2003, Vol. 17(4) pp. 2
sweeteners, 1992, Vol. 06(2) pp. 4
Swettenham, J. G., 1998, Vol. 12(4) pp. 6–7
Symmetrel (amantadine hydrochloride), 2001, Vol. 15(4) pp. 2
Symons, Frank J., 2001, Vol. 15(3) pp. 7
Symptom Outcome Study (SOS), 2002, Vol. 16(2) pp. 4
synaptic junctions, 2000, Vol. 14(4) pp. 6
synesthesia, 1991, Vol. 05(4) pp. 7; 1997, Vol. 11(3) pp. 7.
Syracuse University, 1994, Vol. 08(1) pp. 7; 1994, Vol. 08(2) pp. 2.
systematizing
systematizing and empathizing compared, 2002, Vol. 16(3) pp. 6
Systma, Curt, 1995, Vol. 09(3) pp. 7
Szatmari, Peter, 1996, Vol. 10(4) pp. 5
Szymanski, Ludwik, 1988, Vol. 02(2) pp. 4
Szymanski, Sally, 1992, Vol. 06(2) pp. 7
© copyright 2005, 2006 Autism Research Institute
|
|
